Pharmaceuticals, Biotechnology and Life Sciences
LISBON, Portugal–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results…
BOSTON & LOUISVILLE, Ky.–(BUSINESS WIRE)–Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential…
— Data Show High Rates of Response to Single Infusion of KTE-X19 — — Phase 2 Portion of ZUMA-3 is…
Tumor regressions demonstrate potential for DPX-Survivac immunotherapy in hard-to-treat solid tumors Data correlations of survivin specific T cell levels and…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative…
WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Institute announced the winner of the Mentor of the Year Award, who will be recognized next…
Data show the potential of using neoantigens identified from an individual’s tumor to elicit an immune response to cancer mutations…
INT230-6 well tolerated at all doses given Durable clinical benefit seen in multiple patients Increases in circulating and intratumoral CD4…
In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next…
Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in…